Baidu
map

Int J Nanomed:oMCN@PEG可作为高效抗癌药物递送载体使用

2017-12-03 MedSci MedSci原创

在这项研究中,研究人员成功地制备了一种基于聚乙二醇化氧化介孔碳纳米球(oMCN@PEG)的高效跨膜药物传递载体,是一种简便易行的策略。检测分析显示,oMCN@PEG的尺寸分布范围较小,为90nm左右,亲水性优异,还具有良好的生物相容性以及非常高的阿霉素(DOX)加载效率。载药系统(oMCN@DOX@PEG)在中性pH条件下表现出优异的稳定性,但是pH降低的条件下具有明显的DOX释放。药代动力学研究

在这项研究中,研究人员成功地制备了一种基于聚乙二醇化氧化介孔碳纳米球(oMCN@PEG)的高效跨膜药物传递载体,是一种简便易行的策略。

检测分析显示,oMCN@PEG的尺寸分布范围较小,为90nm左右,亲水性优异,还具有良好的生物相容性以及非常高的阿霉素(DOX)加载效率。载药系统(oMCN@DOX@PEG)在中性pH条件下表现出优异的稳定性,但是pH降低的条件下具有明显的DOX释放。药代动力学研究显示,oMCN@DOX@PEG可延长DOX在血液中的循环时间。此外,研究人员还评价了载药纳米颗粒的体外和体内的内吞作用、细胞毒性和抗癌作用。

结果表明,纳米粒子可有效穿透肿瘤细胞膜,随后释放药物,并可有效抑制癌细胞在体外和体内的生长。尤其是在恶性肿瘤晚期,oMCN@DOX@PEG也可明显抑制癌细胞的转移,提高了荷瘤小鼠的存活时间。

综上所述,该结果表明,oMCN@PEG可能是癌症治疗的一种有希望的抗癌药物递送载体。

原始出处:

Huan Wang, Xiangui Li, et al., Hydrophilic mesoporous carbon nanospheres with high drug-loading efficiency for doxorubicin delivery and cancer therapy. Int J Nanomedicine. 2016; 11: 1793–1806. doi:  10.2147/IJN.S103020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2018-01-14 mei539
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-07 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-05 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-05 wleon8899
  7. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-04 清风拂面

    谢谢分享.学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-03 明天会更好!

    学习了感谢分享!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1645446, encodeId=f74d1645446f8, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Jan 14 08:36:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726917, encodeId=070c1e26917d4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 07 19:36:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811361, encodeId=fa23181136166, content=<a href='/topic/show?id=6d3f8e886e9' target=_blank style='color:#2F92EE;'>#药物递送载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87886, encryptionId=6d3f8e886e9, topicName=药物递送载体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Jul 23 00:36:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308246, encodeId=933b1308246e2, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314728, encodeId=05bf1314e28a3, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608317, encodeId=3207160831e5c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Dec 05 12:36:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266660, encodeId=6c26266660dd, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Dec 04 07:36:10 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266573, encodeId=20d72665e3c8, content=学习了感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Dec 03 23:58:21 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266554, encodeId=71b626655467, content=谢谢!分享.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Sun Dec 03 22:30:29 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-03 微笑人参

    谢谢!分享.谢谢!

    0

相关资讯

艾滋病疫苗载体被证有毒

     对一项大型HIV疫苗实验进行的分析显示,该疫苗并没有疗效,攻克HIV的希望又破灭了。   近日,两项实验的毁灭性结果再次使研究人员对艾滋病病毒(HIV)疫苗战略的评估陷入混乱,而一个广泛应用于疫苗和基因治疗研究的载体也因此引起了他们的担忧。这样的双重打击表明,疫苗作为减缓艾滋病流行的最有效方法,其成功研制仍任重道远。   4月22日,第一个坏消息传来。一个监督正在进行的最大的HIV

无载体药物支架更安全更有效

一、无载体药物支架的结构、性能和分类 目前世界上常用的无载体药物支架有纳米微孔预载药型、支架梁表面结晶化预载药型、支架梁表面粗糙化预载药型、微槽/微盲孔预载药型和后载药型。 二、无载体药物支架的临床研究 1、ISAR-TEST1 ISAR-TEST1是第一个证实无聚合物药物涂层支架抗再狭窄的研究。该研究入选了405例患者,随机入组非聚合物药物涂层的雷帕霉素药物洗脱支架组

J Endod:使用不同载体对white MTA理化性能、抗菌性能和生物特性的影响

这篇研究的目的是为了在white MTA混有水溶性或含牛蒡和茜草(植物提取物)的丙二醇浸膏剂后,评估其理化性能、抗菌性能和生物特性改变。

Mol.Ther.:上海巴斯德所在新型疫苗载体合作研究中取得新进展

腺病毒作为疫苗载体,具有宿主范围广、对人致病性低,与人类基因同源,能有效进行增殖、滴度高等优点,是目前最有应用前景的新型疫苗载体之一。 上海巴斯德所抗感染免疫与疫苗研究组在周东明研究员的带领下,致力于新型疫苗载体、通用型流感疫苗的研发及相关免疫学研究。近日,他们与Wistar研究所研究人员对腺病毒作为疫苗载体开展的合作研究取得了新进展,研究成果以Hexon-modified Recombinan

Biomaterials:新型药物载体能定向将青蒿素运载进入肿瘤细胞

中国科学院强磁场科学中心双聘研究员陈乾旺、中国科学技术大学生命科学学院教授郭振副、安徽医科大学副主任医师王海宝三课题组合作,利用肿瘤细胞内环境的调控,发展了具有pH响应性的多功能药物载体,它能够将疏水药物青蒿素输送到肿瘤细胞内,同时释放出可作为青蒿素抗癌的诱导剂的Fe2+,从而大大提高了抗癌药效。相关研究在线发表在《生物材料》(Biomaterials)上。目前临床上广泛使用的抗癌药物仍为人工合成

慢病毒载体基因治疗罕见遗传性疾病取得初步成功

肾上腺脑白质失养症(X-linked adrenoleukodystrophy)是一种罕见的遗传病,昨天在华盛顿美国基因和细胞治疗年会上,科学家宣布用基因治疗17名患者16名获得了初步成功,经过基因工程病毒为载体的基因治疗2年后,16名患者仍然存活。这一研究是过去研究结果的进一步扩大,会进一步推动肾上腺脑白质失养症基因治疗的临床应用速度。In the brain of an ALD patient

Baidu
map
Baidu
map
Baidu
map